Etigilimab (MPH313)
Advanced Solid Tumors
Phase 1bOut-licensed
Key Facts
About Mereo BioPharma
Mereo BioPharma is a UK-based biopharma founded in 2015 with a mission to deliver impactful therapies for rare diseases with limited treatment options. Its core strategy involves identifying, in-licensing, and developing late-stage clinical assets that have been deprioritized by larger pharmaceutical companies, leveraging deep industry relationships and a patient-centric approach. Key achievements include a foundational asset acquisition from Novartis, a transformative 2019 merger with OncoMed that secured a NASDAQ listing, and a strategic partnership with Ultragenyx for its lead osteogenesis imperfecta program.
View full company profileTherapeutic Areas
Other Advanced Solid Tumors Drugs
| Drug | Company | Phase |
|---|---|---|
| NT219 | Purple Biotech | Phase 1/2 |
| INDP-101 | Indaptus Therapeutics | Phase 1 |
| NST-101 (estimated) | Novastage Pharmaceuticals | Phase 1/2 |
| Meta10-TILs | Leman Biotech | Phase 1 |
| PM14 | PharmaMar | Phase 1/2 |
| Ecubectedin (PM54) | PharmaMar | Phase 1 |
| M8891 | Merck KGaA | Phase 1/2 |
| P-002 | Panacea Biotec | Phase 1/2 |
| Undisclosed kinase inhibitor | Tyligand Bioscience | Phase 1 |
| TYK-001 | TYK Medicines | Phase 1/2 |
| PT-112 | SciClone Pharmaceuticals | Phase 1 |
| AP-202 | Advance Pharmaceutical | Phase 1/2 |